EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma

L Aceituno iD, C Magyar iD, P Tabrizian, R Marino, K Watt, D Chascsa, G Schnickel, V Banz, F Alconchel, Celia Martagon, C Moctezuma iD, T Baker und 10 weitere

Alimentary Pharmacology & Therapeutics · 2026-05 · 63 (10) · 1369-1379

DOI: 10.1111/apt.70528 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 04.02.2026. Verfasst von L Aceituno und 21 weiteren Autor:innen. Beteiligte Einrichtung: Multi-Organ Transplant, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Liver Transplantation, Liver Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have emerged as promising agents for the management of advanced HCC. By reducing tumour burden, ICIs may serve as a downstaging/bridging tool to improve transplant candidacy. The aim of this study was to assess the safety of patients receiving pre‐LT ICIs.

Methods

Multicenter, retrospective cohort study from January 2018 to December 2024, including 48 patients who received ICIs prior to LT (ICI cohort). A control cohort (non‐ICI cohort) was built (1:3) using propensity score matching including 144 patients who underwent LT for HCC without prior ICI.

Results

Within the ICI cohort ( N = 48) rejection occurred in 9 patients (18.8%), all biopsy‐proven, with a median onset of 31 days post‐LT (12.0–182.0). The median washout period was 60 days (13–96). Patients experiencing rejection had shorter washout periods ( p = 0.029). All rejection episodes were successfully managed; two were steroid‐resistant, one requiring re‐transplantation. There were no rejection‐related deaths. Of the 5 patients with HCC recurrence, 60% received ICI for < 90 days ( p = 0.027). Comparison between the ICI and non‐ICI cohort revealed no significant differences in rejection rates (18.8% vs. 19.4%, p = 0.916), graft failure, HCC recurrence, or overall mortality. Overall survival (OS) did not differ between ICI and non‐ICI patients ( p = 0.625) or between those with and without rejection ( p = 0.119). Rejection was not associated with increased mortality, with deaths primarily attributed to infection or HCC recurrence.

Conclusion

Our results demonstrate that rejection rates were similar in patients receiving ICIs pre‐LT and it can be safely managed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsCarcinoma, HepatocellularLiver TransplantationLiver NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedGraft RejectionAgedNeoplasm Recurrence, Local

Stichwörter der Autor:innen

hepatocellular carcinomaimmune checkpoint inhibitorsliver transplantationrecurrencerejection

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Multi-Organ Transplant, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • University Health Network, HPB Surgical Oncology, Toronto, Ontario, Canada.
  • Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: L Aceituno, C Magyar, C Moctezuma

Zitieren

APA

Aceituno, L., Magyar, C., Tabrizian, P., Marino, R., Watt, K., Chascsa, D., Schnickel, G., Banz, V., Alconchel, F., Martagon, C., Moctezuma, C., Baker, T., Nwaduru, C., Krendl, F. J., Oberhuber, R., Ruiz-Ortega, L., Demers, C., Bucur, R., O'Kane, G., …, & Sapisochin, G. (2026). Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics, 63(10), 1369-1379. https://doi.org/10.1111/apt.70528

Vancouver

Aceituno L, Magyar C, Tabrizian P, Marino R, Watt K, Chascsa D, et al. Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. 2026;63(10):1369-1379. doi:10.1111/apt.70528

BibTeX
@article{Aceituno2026,
  author = {Aceituno, L and Magyar, C and Tabrizian, P and Marino, R and Watt, K and Chascsa, D and Schnickel, G and Banz, V and Alconchel, F and Martagon, Celia and Moctezuma, C and Baker, T and Nwaduru, C and Krendl, F J and Oberhuber, R and Ruiz-Ortega, L and Demers, C and Bucur, R and O'Kane, G and Vogel, A and Mínguez, B and Sapisochin, G},
  title = {Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {10},
  pages = {1369--1379},
  doi = {10.1111/apt.70528}
}
Kostenlos starten →